This database contains 175 studies, archived under the term: "administration & dosage"
Click here to filter this large number of results.
Longitudinal changes of fractional anisotropy in Alzheimer’s disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study
Likitjaroen, Y.,
Meindl, T.,
Friese, U.,
Wagner, M.,
Buerger, K.,
Hampel, H.,
Teipel, S. J.
Diffusion tensor imaging (DTI) demonstrates decline of fractional anisotropy (FA) as a marker of fiber tract integrity in Alzheimer’s disease (AD). We aimed to assess the longitudinal course of white matter microstructural changes in AD and healthy elderly control (HC) subjects and to evaluate the effects of treatment with the cholinesterase inhibitor galantamine on white […]
Two galantamine titration regimens in patients switched from donepezil
Engedal, K.,
Davis, B.,
Richarz, U.,
Han, J.,
Schäuble, B.,
Andreasen, N.
Objectives: In addition to inhibiting acetylcholinesterase, galantamine has allosteric-modulating activity at nicotinic receptors. This may make galantamine an attractive option for patients starting treatment for Alzheimer’s disease (AD), but also for those who have not benefited from their current therapy. This study explored outcomes in subjects with AD transitioning from donepezil because of insufficient tolerability […]
Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer’s disease
Salloway, Stephen,
Mintzer, Jacobo,
Cummings, Jeffrey L.,
Geldmacher, David,
Sun, Yijun,
Yardley, Jane,
Mackell, Joan
To better understand responses in the large number of US-based patients included in a global trial of donepezil 23 mg/d versus 10 mg/d for moderate-to-severe Alzheimer’s disease (AD), post hoc exploratory analyses were performed to assess the efficacy and safety in US and non-US (rest of the world [RoW]) patient subgroups. In both subgroups, donepezil […]
Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer’s disease: a subgroup analysis in patients already taking or not taking concomitant memantine
Doody, Rachelle S.,
Geldmacher, David S.,
Farlow, Martin R.,
Sun, Yijun,
Moline, Margaret,
Mackell, Joan
Background/aims: A large multicenter trial of donepezil 23 mg/day versus donepezil 10 mg/day for moderate-to-severe Alzheimer’s disease allowed patients taking concomitant memantine. We evaluated the efficacy/safety of donepezil 23 and 10 mg/day in this trial, with respect to concomitant memantine use.; Methods: Prespecified analysis of data from a 24-week, randomized, double-blind trial. Patients were randomized […]
Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer’s disease
Cummings, Jeffrey,
Froelich, Lutz,
Black, Sandra E.,
Bakchine, Serge,
Bellelli, Giuseppe,
Molinuevo, José L.,
Kressig, Reto W.,
Downs, Pamela,
Caputo, Angelika,
Strohmaier, Christine
Aim: Determine whether patients with Alzheimer’s disease demonstrating functional and cognitive decline, following 24-48 weeks of open-label treatment with 9.5 mg/24 h (10 cm(2)) rivastigmine patch, benefit from a dose increase in a double-blind (DB) comparative trial of two patch doses.; Methods: Patients meeting prespecified decline criteria were randomized to receive 9.5 or 13.3 mg/24 […]
Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures
Galasko, Douglas R,
Peskind, Elaine,
Clark, Christopher M.,
Quinn, Joseph F.,
Ringman, John M.,
Jicha, Gregory A.,
Cotman, Carl,
Cottrell, Barbara,
Montine, Thomas J.,
Thomas, Ronald G.,
Aisen, Paul
Objective: To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers.; Design: Double-blind, placebo-controlled clinical trial.; Setting: Academic medical centers.; Participants: Subjects with mild to moderate Alzheimer disease.; Intervention: Random assignment to treatment for 16 weeks with 800 IU/d of vitamin E (α-tocopherol) plus 500 mg/d of vitamin C […]
The effect of stimulation therapy and donepezil on cognitive function in Alzheimer’s disease. A community based RCT with a two-by-two factorial design
Andersen, Fred,
Viitanen, Matti,
Halvorsen, Dag S.,
Straume, Bjørn,
Wilsgaard, Tom,
Engstad, Torgeir A.
Background: Progressive neurodegeneration in Alzheimer’s disease (AD) induces cognitive deterioration, and there is controversy regarding the optimal treatment strategy in early AD. Stimulation therapy, including physical exercise and cholinesterase inhibitors are both reported to postpone cognitive deterioration in separate studies. We aimed to study the effect of stimulation therapy and the additional effect of donepezil […]
Efficacy of Souvenaid in mild Alzheimer’s disease: results from a randomized, controlled trial
Scheltens, Philip,
Twisk, Jos W.R.,
Blesa, Rafael,
Scarpini, Elio,
von Arnim, Christine A. F.,
Bongers, Anke,
Harrison, John,
Swinkels, Sophie H. N.,
Stam, Cornelis J.,
de Waal, Hanneke,
Wurtman, Richard J.,
Wieggers, Rico L.,
Vellas, Bruno,
Kamphuis, Patrick J. G. H.
Souvenaid aims to improve synapse formation and function. An earlier study in patients with Alzheimer’s disease (AD) showed that Souvenaid increased memory performance after 12 weeks in drug-naïve patients with mild AD. The Souvenir II study was a 24-week, randomized, controlled, double-blind, parallel-group, multi-country trial to confirm and extend previous findings in drug-naïve patients with […]